Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
This study is to help determine the most effective type or combination of treatments to offer patients seeking lung cancer screening who are smokers to help them reduce the number of cigarettes they smoke, or quit smoking. The investigators long term goal is to increase the benefits of lung cancer screening by providing a blue print of best practices for screening sites to deliver tobacco treatment to their patients who are smokers, in a way that does not add burden to screening site staff and increases the chances of patients quitting smoking.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 3 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Nov 24, 2025 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Interventions being studied
- Behavioral: Motivational Interviewing (MI); Drug: Nicotine Replacement Therapy (NRT); Drug: Nicotine Lozenge; Behavioral: Message Framing; Other: saliva sample
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Site Eligibility (as per SC self-report) \& Must be designated as an American College of Radiology (ACR) designated lung cancer screening site
- Reports at least one year of lung cancer screening experience
- Reports conducting at least 20 new initial screenings per month Site Coordinator (SC) Eligibility (as per SC self-report)
- Employed as a full-time Site Coordinator at participating lung cancer screening site Patient Eligibility (as per self-report)
- Between the ages of 50-80 years old
- Seeking baseline or annual follow-up LDCT lung cancer screening
- Have at least a 20 pack-year history of smoking
- Currently a smoker, defined as self-reported cigarette smoking (some days, every day) within the past 30 days.
- Must be reachable by telephone
- Must be English or Spanish speaking due to the study materials being available in only these languages and limited available resources for translation.
- Patient (as per self-report)
- NRT is medically contraindicated (e.g., recent heart attack within the last 2 weeks or, unstable/worsening angina).
- Smokers who are receiving other tobacco treatment services or have used cessation medications (NRT, bupropion, varenicline) within the past month.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Southern California (Data Collection Only)Los Angeles, California
- John Muir HealthWalnut Creek, California
- WellStar Health SystemLa Grange, Georgia
- Rush University Medical CenterChicago, Illinois
- Riverside HealthcareKankakee, Illinois
- St. Mary Medical Center, Community Healthcare SystemCrown Point, Indiana
- MercyOne Des Moines Medical Center (Data Collection Only)Des Moines, Iowa
- Maine Medical Center Cancer InstituteScarborough, Maine
- Henry Ford Hospital (Data collection only)Detroit, Michigan
- Munson HealthcareTraverse City, Michigan
- NYU Winthrop HospitalMineola, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 24, 2025. Always confirm current availability with the study team.